Italia markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,3500-0,1900 (-7,48%)
Alla chiusura: 04:00PM EDT
2,3781 +0,03 (+1,20%)
Dopo ore: 06:52PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,5400
Aperto2,5200
Denaro2,3500 x 100
Domanda2,3700 x 1100
Min-Max giorno2,3200 - 2,5250
Intervallo di 52 settimane2,2300 - 6,0500
Volume2.569.762
Media Volume2.289.668
Capitalizzazione490,642M
Beta (mensile su 5 anni)0,86
Rapporto PE (ttm)N/D
EPS (ttm)-1,7800
Prossima data utili31 lug 2024 - 05 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A11,51
  • GlobeNewswire

    Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company’s financial operations and business strategy and will serve as a member of the Leadership Team. “Geoff’s extensive experience in biotechnology across all

  • GlobeNewswire

    Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune CellsEvaluation of Cloak™ Technology to Engineer Allogeneic Cells from Detection by the Host Immune System Preclinical Validation of ALLO-182, an AlloCAR T™ Candidate Targeting Claudin18.2 for the Treatment of Gastric and Pancreatic Cancers SOUTH SAN FRANCISCO,

  • GlobeNewswire

    Allogene Therapeutics Announces Participation in September Investor Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming investor conference in September. Baird 2023 Global Healthcare ConferenceTuesday, September 12, 202312:45PM PT/3:45PM ET Any available webcasts will be posted to the Company's website at www.allogene.com under the In